BIO News and Press, Bio-Rad Laboratories Inc. Class A From 08/03/23

2023-08-03 23:33:03 ET Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Conference Call August 3, 2023 17:00 ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chie...

2023-08-03 16:47:10 ET Bio-Rad Labs press release ( NYSE: BIO ): Q2 Non-GAAP EPS of $3.00 beats by $0.32 . Revenue of $681.11M (-1.4% Y/Y) misses by $14.72M . Updated 2023 Outlook: The company currently expects non-GAAP currency-neutral revenue growth of ap...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023. Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $6...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agre...

2023-07-25 07:30:47 ET Despite posting better than expected financials for Q2 2023, Danaher Corporation ( NYSE: DHR ) slipped ~5% pre-market Tuesday as the U.S. life sciences company lowered its full-year outlook amid falling COVID-related revenue. Danaher’s ( DHR ...

2023-07-21 11:43:42 ET Sartorius AG ( OTCPK:SARTF ) traded sharply higher on Friday, rallying the shares of its U.S. peers, after the German life sciences company posted its Q2 2023 results, indicating a gradual recovery following a post-pandemic contraction in demand. Notable gaine...

2023-07-21 05:52:56 ET U.S. stock futures inched higher during Friday's early hours of trade after the Dow celebrated its longest rise since 2017, with a ninth day of gains. Nasdaq futures are also recovering after their worst session since early March . Here are some of Friday's bi...

2023-07-20 16:59:39 ET Bio-Rad Laboratories ( NYSE: BIO ) has approved a new $500 million stock buyback program, the company said Thursday. The company said any shares acquired will be available for general corporate purposes, including supporting employee stock plans, f...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market. Management will discuss these results in a c...